Alliqua (ALQA) Misses Q1 EPS by 3c; Maintains Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Alliqua BioMedical, Inc. Reports First Quarter of Fiscal Year 2017 Financial Results
May 9, 2017 7:00 AM EDTYARDLEY, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced financial results for the first quarter ended March 31, 2017.
First Quarter 2017 Summary:
Total revenue from continuing operations increased 16% year-over-year to $4.6 million.Product revenue from continuing operations increased 28% year-over-year to $4.4 million.Gross margin was 64%, compared to 60% in the same period last year.Adjusted EBITDA loss decreased by $1.8... More